• +353-1-416-8900(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)

PRODUCT FILTERS

REGION

1,141
109
75
71
68

COUNTRY

70
22
16
10
9

CATEGORIES

  • 574
  • 118
  • 550
  • 75
  • 526
  • 43
  • 505
  • 18
  • 18
  • 23

PRICE

970
1,199
1,762
2,980

PUBLISHED

39
233
665
2,980

PRODUCT TYPE

2,406
494
70
7
1
1
1

Oncology

The American Cancer Society forecasts that 1,638,910 new cancer cases will occur in the United States in 2012. As cancer rates worldwide are increasing, the oncological sector of the pharmaceutical industry is growing fast and it will continue to provide business opportunities in the next years. However, cancer trials are some of the most complex, time consuming and expensive across all therapeutic areas. What are the new paths to success in this lucrative but challenging market?

Find out the answer in the reports, books, and subscriptions listed under Research and Markets’ Oncology category. Our top-quality publications from industry experts cover every aspect of cancer drug therapy, with a focus on: Lung Cancer, Breast Cancer, Prostate Cancer, Leukaemia, Lymphoma, Ovarian Cancer, Colon Cancer, Cervical Cancer, Brain Cancer and Bladder Cancer. So read on for the latest clinical trials, pipeline reviews, industry news, and commercial opportunities.

Key players featured in our publications include Abbott, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Johnson & Johnson, Merck, Novartis, Pfizer, Roche, Sanofi-Aventis, Wyeth, and many more. Show Less
Read more

PRODUCT TITLE
ID Signaling Pathway in Oncology Drug Pipeline Update 2014 ID Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

ID Signaling Pathway in Oncology Drug Pipeline Update 2014

Inhibitor of DNA binding (ID) proteins are members of the helix-loop-helix (HLH) family of proteins which lack a DNA binding domain themselves but bind to other family members inhibiting their DNA binding...

July 2014
FROM
Colorectal Cancer Drug Pipeline Update 2014 Colorectal Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Colorectal Cancer Drug Pipeline Update 2014

Until a decade ago, 5FU/leucovorin formed the mainstay of colorectal cancer treatment but Camptosar and Eloxatin quickly established themselves as components of gold-standard therapy. The advent of...

July 2014
FROM
Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Androgen Receptor Signaling Pathway in Oncology Drug Pipeline Update 2014

The androgen receptor signaling pathway activates the SMAD signaling module. There are today 332 companies plus partners developing 441 Androgen Receptor drugs in 1457 developmental projects in cancer....

July 2014
FROM
Gap Junctions in Oncology Drug Pipeline Update 2014 Gap Junctions in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Gap Junctions in Oncology Drug Pipeline Update 2014

Gap junctions contain intercellular channels that allow direct communication between the cytosolic compartments of adjacent cells. Each gap junction channel is formed by docking of two 'hemichannels',...

July 2014
FROM
GnRH Signaling Pathway in Oncology Drug Pipeline Update 2014 GnRH Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

GnRH Signaling Pathway in Oncology Drug Pipeline Update 2014

Gonadotropin-releasing hormone (GnRH) secretion from the hypothalamus acts upon its receptor in the anterior pituitary to regulate the production and release of the gonadotropins, LH and FSH. There...

July 2014
FROM
TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014 TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

TNF-Alpha Signaling Pathway in Oncology Drug Pipeline Update 2014

The TNF-alfa signaling pathway stimulates the MAPK signaling module and activates NFkB. There are today 366 companies plus partners developing 550 TNF-alpha pathway targeting drugs in 2048 developmental...

July 2014
FROM
FSH Signaling Pathway in Oncology Drug Pipeline Update 2014 FSH Signaling Pathway in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

FSH Signaling Pathway in Oncology Drug Pipeline Update 2014

Follicle stimulating hormone (FSH) binds to FSH-receptor which is coupled to Gs protein that in turn activates cAMP dependent protein kinases (PKA) and thus triggers FSH signaling which continues further...

July 2014
FROM
p53 Signaling Pathway in Cancer Drug Pipeline Update 2014 p53 Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

p53 Signaling Pathway in Cancer Drug Pipeline Update 2014

p53 activation is induced by a number of stress signals, including DNA damage, oxidative stress and activated oncogenes. The p53 protein is employed as a transcriptional activator of p53-regulated genes....

July 2014
FROM
ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014 ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

ErbB Signaling Pathway in Cancer Drug Pipeline Update 2014

The ErbB family of receptor tyrosine kinases (RTKs) couples binding of extracellular growth factor ligands to intracellular signaling pathways regulating diverse biologic responses, including proliferation,...

July 2014
FROM
Mitochondrial Drugs in Oncology Drug Pipeline Update 2014 Mitochondrial Drugs in Oncology Drug Pipeline Update 2014 - Product Thumbnail Image

Mitochondrial Drugs in Oncology Drug Pipeline Update 2014

Focusing on mitochondria has recently become an intriguing target for cancer therapy. It is well known that mitochondrial activity in tumor cells is suppressed and exploiting the differences in mitochondrial...

July 2014
FROM
Head and Neck Cancer Drug Pathway Analyzer 2014 Head and Neck Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Head and Neck Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 149 targeted molecular therapies known to affect more than 241 specific intracellular signaling pathways...

July 2014
FROM
Breast Cancer Drug Pathway Analyzer 2014 Breast Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Breast Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 532 targeted molecular therapies known to affect more than 253 specific intracellular signaling pathways...

July 2014
FROM
Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014 Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014 - Product Thumbnail Image

Conjugated Drugs in Oncology: Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 262 conjugated drugs known to affect more than 206 specific intracellular signaling pathways for the...

July 2014
FROM
Transcriptional Misregulation in Cancer Drug Pipeline Update 2014 Transcriptional Misregulation in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Transcriptional Misregulation in Cancer Drug Pipeline Update 2014

There are today 222 companies plus partners developing 297 transcriptional misregulation targeting drugs in 1186 developmental projects in cancer. In addition, there are 3 suspended drugs and the accumulated...

July 2014
FROM
HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2014 HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

HIF-1 Signaling Pathway in Cancer Drug Pipeline Update 2014

Cancer cells are characterized by rapid proliferation and require adaptive metabolic responses to allow continued biosynthesis and cell growth in the setting of decreased oxygen (O(2)) and nutrient...

July 2014
FROM
Lymphoma Drug Pathway Analyzer 2014 Lymphoma Drug Pathway Analyzer 2014 - Product Thumbnail Image

Lymphoma Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 350 targeted molecular therapies known to affect more than 235 specific intracellular signaling pathways...

July 2014
FROM
Bladder Cancer Drug Pathway Analyzer 2014 Bladder Cancer Drug Pathway Analyzer 2014 - Product Thumbnail Image

Bladder Cancer Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 99 targeted molecular therapies known to affect more than 215 specific intracellular signaling pathways...

July 2014
FROM
Protein Kinase Inhibitors Drug Pathway Analyzer 2014 Protein Kinase Inhibitors Drug Pathway Analyzer 2014 - Product Thumbnail Image

Protein Kinase Inhibitors Drug Pathway Analyzer 2014

Extra value: One year of free online updates included with this product There are today at least 963 protein kinase inhibitor drugs known to affect more than 250 specific intracellular signaling pathways...

July 2014
FROM
Targeting Tight Junctions in Cancer Drug Pipeline Update 2014 Targeting Tight Junctions in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Targeting Tight Junctions in Cancer Drug Pipeline Update 2014

Epithelial tight junctions (TJs) are composed of at least three types of transmembrane protein -occludin, claudin and junctional adhesion molecules (JAMs)- and a cytoplasmic 'plaque' consisting of many...

July 2014
FROM
Targeting Metabolic Pathways in Cancer Drug Pipeline Update 2014 Targeting Metabolic Pathways in Cancer Drug Pipeline Update 2014 - Product Thumbnail Image

Targeting Metabolic Pathways in Cancer Drug Pipeline Update 2014

There are today 149 companies plus partners developing 156 metabolic pathways targeting drugs in 436 developmental projects in cancer. In addition, there are 2 suspended drugs and the accumulated number...

July 2014
FROM
Loading Indicator

Our Clients

Our clients' logos